HFX for NSBP

About Nevro

Nevro's mission is to free patients from the burden of chronic pain through its innovative neuromodulation technology. Its key achievement was the 2015 FDA approval of the Senza SCS System for 10 kHz Therapy, establishing a new standard in paresthesia-free spinal cord stimulation. The company's strategy centers on its comprehensive HFX solution, which integrates proprietary high-frequency stimulation, multi-waveform capabilities, and extensive clinical support to drive adoption in the large and growing chronic pain market. Nevro has expanded globally, treating tens of thousands of patients and securing specific FDA indications for conditions like painful diabetic neuropathy.

Therapeutic Areas